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Preface 
 
 
 
 
Development of new molecular markers in 
immunohematology and oncology 
 
 
 
The advances in molecular medicine lead continuously to the discovery 
of new targets for new possible therapeutic approaches. At the same 
time the possibility and the need for more efficient biological markers 
is increased, as well as the necessity of new functional tests or 
diagnostic algorithms that could be able to optimize monitoring and 
follow-up of diseases, or obtain an earlier diagnosis. 
The works presented here, though focusing on different topics, aim to 
shed new light on the biological role of newly identified cell subsets 
and molecules, and their importance as phenotypical and functional 
markers in human immunohematology and oncology. 
The progresses obtained in the field of cellular immunology, and in the 
definition of specific T cell subsets in particular, contributed to increase 
our knowledge on the pathogenesis of several diseases which recognize 
an immunological trigger, as well as on the mechanisms that regulate 
the omeostasis of cancer cells. These discoveries have allowed the 
development of new, more efficient drugs, if compared to traditional 
standard therapies. The study of cellular protagonists of innate and 
adaptive immunity, moreover, led to the acquisition of new keys to 
obtain a wider overview of some diseases where the immune system 
activation acts as a balance between two possible evolutions: such is the 
case, for example, of HCV-related hepatitis. The prosecution of these 
studies holds the promise to lead to new information for predicting the 
natural history of the disease, and to the elaboration of new laboratory-
clinical indexes for its monitoring. 
The study of growth and proliferation dynamics of Cytokine-Induced 
Killer cells (CIK) is nowadays important for the assessment of the 
functionality of cells destined to clinical use, in order to obtain safer 
and more efficient products. At the same time, the development of new 
biological markers and functional tests which can be able to provide 
more information about viability, functionality and duration of infused 
cells is of great interest. 
In clinical oncology, a great effort is being made in order to discover 
efficient biological markers able to early detect the occurring of a 
malignant disease. Such biological markers would, for instance, be of 
great support in the early diagnosis of malignant melanoma, the most 
dangerous neoplasia of skin. The omeostasis and the pathophysiology 
of normal melanocytes, as well as malignant melanocytes have 
currently being dissected in order to achieve this goal. 
The data collected in the present studies are a result of independent 
research, and no conflict of interest exists. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.  Circulating CD4
+
CD25
+
 and liver 
infiltrating Foxp3
+
 cells as new 
markers in chronic HCV-associated 
liver disease 
 
 
 
 
 
1.1 Introduction 
 
Hepatitis C virus (HCV)-associated chronic liver disease is a chronic 
liver inflammation where immune system is unable to efficiently clear 
the viral infection. Although viral factors are certainly involved, several 
pathophysiological alterations involving the host immune system have 
also been suggested to take part in the complex pathogenesis of the 
disease. It is now well known that a strong early cellular response 
elicited by effector CD4
+
 and CD8
+
 T cells could in some cases be able 
to clear the virus and solve the infection. However, in most cases the 
infection becomes chronic. Several humoural and cellular regulatory 
mechanisms has been claimed to be involved in such phenomenon. One 
possibility is that the naturally tolerogenic liver microenvironment is 
responsible for an inappropriate biochemical support for an efficient 
viral clearance, therefore leading to the selection of lymphocyte subsets 
different from Th1-oriented effector cells (1, 2). Understanding the role 
of all the actors of the immune system is therefore crucial for reaching 
the goal to finding an effective therapy. In line with this concept, the 
study of new markers of cell-mediated immunity is of great interest. 
Previous studies have raised the possibility of an involvement of T 
regulatory cells (Tregs) in the natural history of a chronic liver 
inflammation (3). In fact, in HCV-related chronic hepatitis, HCV-
specific CD4
+
 T cells displaying a regulatory phenotype have been 
identified, and the percentages of peripheral blood Tregs have been 
correlated to the circulating viral load (4). For these reasons, Tregs have 
been thought to be involved in the establishment of a chronic hepatitis 
and in the defective virus clearance ability of effector cells. However, 
despite clones of HCV-specific T regulatory cells have been proved to 
develop during infection and to suppress the anti-viral cytotoxic CD8
+
 
cell response, the real contribution of this lymphocyte subset to the 
pathogenesis of HCV chronic infection still remains uncertain (5). 
 
 
 
1.2 Scientific Background 
 
Immune system in HCV infection. Hepatitis C virus frequently elicits 
only mild immune responses so that it can often establish a chronic 
infection where HCV antigens persist and continue to stimulate the 
immune system. Antigen persistence then leads to profound changes in 
the infected host's immune responsiveness, and eventually contributes 
to the pathology of chronic hepatitis. Along with the natural history of 
chronic hepatitis, the immune system undergoes several changes 
concerning innate immunity (interferons, natural killer cells), adaptive 
immune responses (immunoglobulins, T cells), and mechanisms of 
immune regulation (regulatory T cells). In general, a strong anti-HCV 
immune response is frequently associated with acute severe tissue 
damage. In chronic hepatitis C, however, the effector arms of the 
immune system either become refractory to activation or take over 
regulatory functions. Taken together these changes in immunity may 
lead to persistent liver damage and cirrhosis. Consequently, effector 
arms of the immune system play a pivotal role in triggering the 
mechanisms of inflammation, necrosis and progression to cirrhosis. 
Thus, avoiding a strong, sustained antiviral immune response with 
initial tissue damage, takes the infected host to virus-triggered 
immunopathology,  which ultimately leads to cirrhosis and liver cancer 
(6). 
The most conclusive experiments to suggest an important role for T 
cells in protective immunity against HCV stem from chimpanzee 
experiments: depletion of CD8
+
 T cells in animals, which had recovered 
from previous hepatitis C, resulted in prolonged viraemia, and viral 
clearance was correlated to recovery of HCV-specific CD8
+
 T cells (7). 
Likewise, depletion of CD4
+
 T cells resulted in abrogation of a 
previously protective immune response (8). In acute hepatitis C, strong 
HCV-specific CTL (9, 10) and Th1 type CD4
+
 T helper cell responses 
have consistently been reported to be closely associated with a self-
limited course of HCV infection. Moreover, several groups have 
reported an inverse relationship between the strength of the CTL 
response and HCV viral loads, further suggesting that in principle it is 
possible for cellular immunity to control HCV infection (11). A 
substantial proportion of individuals who ultimately develop chronic 
hepatitis C also generates HCV-specific CD4
+
 and CD8
+
 T cell 
responses during the early acute phase of infection and may transiently 
gain some control over HCV (12). However, early T cell responses 
decline to almost undetectable levels later on, and initial control over 
HCV replication is lost, though HCV-specific CD4
+
 and CD8
+
 T cells 
can be found enriched within the liver parenchyma (13, 14). Thus, 
chronic hepatitis C is characterized by a progressive functional 
exhaustion of HCV-specific CD4
+
 and CD8
+
 T cells (15). Exhausted T 
cells exhibit characteristic abnormalities: they show increased 
expression of inhibitory receptors, such as programmed death-1 (PD-1), 
cytotoxic T lymphocyte antigen 4 (CTLA-4), T cell immunoglobulin 
and mucin domain-containing molecule 3, corresponding to up-
regulated expression of their cognate ligands in the liver (16-18). 
Conversely, functional recovery of HCV-specific T cells can be 
achieved experimentally by the combined blockade of CTLA-4 and 
PD-1 signalling. Thus, prolonged exposure appears to be the 
mechanism that leads to T cell dysfunction in chronic hepatitis C (19). 
In the last years, increasing evidences have shown how other important 
actors play a role in HCV-related chronic liver disease.  Among these, 
regulatory T cells. 
 
Regulatory T cells. Regulatory T cells play an important role in 
maintaining self-tolerance through their inhibitory functions on effector 
T cells, preventing the development of autoimmunity (20). While 
thymic deletion of self-reactive T cells provides a first line mechanism 
of central tolerance, Tregs represent a peripheral system to maintain 
self-tolerance and prevent over-exuberant immune responses; thanks to 
this second mechanism, self-reactive T cells escaped to intrathymic 
selection are controlled at the periphery; moreover, peripheral 
regulation is able to control excessive effector T cell responses against 
exogenous antigens, when their activation becomes deleterious, or to 
prevent the functional exhaustion of effector cells, thus granting a long 
term immunity (21). Mice with mutations in a critical Treg gene 
(Foxp3) develop a fatal lymphoproliferative syndrome characterized by 
multi-organ inflammation (22). Immunologically, Tregs comprise a 
subset of CD4
+
 lymphocytes that suppresses activation, proliferation, 
and effector responses of both innate and adaptive immune cells. 
Functional Tregs also express the interleukin-2 (IL-2) receptor α-chain 
(CD25), although activated conventional T cells also transiently express 
CD25. Like conventional T cells, Tregs require T cell receptor (TCR) 
stimulation and costimulation for activation (23). Natural Tregs 
(nTregs) are a Treg subset derived centrally in the thymus and represent 
about 1-3% of all CD4
+
 T cells. They express surface markers of 
activated, antigen primed, memory T cells: CD25, CD45RBlow, 
CD62L, CD103, cytotoxic T lymphocyte antigen-4 (CTLA-4), and 
glucocorticoid-induced tumor necrosis factor receptor (GITR) (21). 
Regulatory T cells might act multi-directionally by preventing 
migration of effector cells, or inhibiting their cooperation with antigen-
presenting cells (APC) and thus inducing anergy. They are also capable 
of killing effector cells or APCs via direct cell-cell contact. Treg cells 
require T-cell receptor (TCR) stimulation to exert suppression, 
however, once activated they mediate inhibitory effects without antigen 
specificity. IL-2 is also specifically required for the Treg maintenance 
and expansion (21). 
Apart from natural Treg cells originating in the thymus (nTreg), other 
Treg subsets can be induced from peripheral naïve T CD4
+
CD25
neg
 
cells (Peripherally-induced Tregs, adaptive [aTregs], or Induced Tregs 
[iTregs]). These subsets can arise under specific influences of the 
microenvironment, and acquire different phenotypical features and 
functional properties. The so called Tr1 cells develop under the control 
of IL-10-conditioned DCs: they are marked by a high IL-10 production; 
this subtype does not seem to express FOXP3. Another subset is 
induced from peripheral unprimed CD4
+
 T cells under the influence of 
TGF-β and is phenotypically indistinguishable from thymus-derived 
nTregs, including the expression of FOXP3 protein (24, 25). 
Circulating and tissue iTreg numbers depend on anatomic location as 
well as specific inflammatory environmental conditions. Abbas and 
other authors recently published recommendations for Treg 
nomenclature (26). Many efforts are currently being made in order to 
use Tregs as adoptive T cell immunotherapy; however, clinical 
implementation of protocols employing Treg cellular products is still 
challenging (27). 
 
Regulatory T cells in HBV and HCV infection. Since the first report on 
the presence of regulatory T cells in the liver during viral infections by 
MacDonald and coworkers in 2002 (28), the scientific debate had 
focused on the question whether the action of Tregs in the context of a 
chronic infection is useful as it limits the extent of tissue damage or 
rather detrimental because of its negative regulation of the effector cell 
response. This issue still remains a matter of controversies. Many 
works have demonstrated how Treg cells are able to impair the response 
of effector cells to HCV antigens (29-31). In particular, they have been 
shown to suppress IFN-γ secretion by CD4+ and CD8+ T cells and 
inhibit their proliferation in response to antigenic stimuli. Recently 
CD8
+
 T cells have been reported in the livers of patients with chronic 
hepatitis C which were considered to represent CD8
+
 regulatory T cells, 
because they secrete IL-10 and suppress in vitro proliferation of liver-
derived T cells (32). On the other hand, Tregs have been proved to limit 
the activation-induced cell exhaustion and apoptosis of effector cells, 
thus granting the survival of a memory pool and a long lasting 
immunity (33-35). Of note, intrahepatic regulatory T cells in chronic 
hepatitis C also produced substantial amounts of IL-8, and isolated 
Tregs as well as Treg clones activated fibrogenic genes of hepatic 
stellate cells in vitro (36). High intrahepatic IL-8 mRNA levels in 
chronic hepatitis C have been linked with progression of fibrosis and 
CD4
+
 Tregs are enriched in the liver (37-41). 
 
Future developments. In order to acquire more knowledge on this issue, 
further studies should aim to correlate the presence, the phenotypical 
features and the functional ability of intrahepatic Tregs to the clinical, 
long term evolution of HCV infection. While monitoring of the clinical 
evolution of HCV infection can be easily achieved by routine follow-up 
including serum transaminase levels, viremia load and ultra-sound scan, 
intra-hepatic detection and characterization of Tregs would require the 
establishment of a defined liver biopsy schedule, during long term 
follow-up, and the consequent execution of immunohistochemical 
studies in order to fully characterize the cellular populations present 
within the liver infiltrates; in this context, tridimensional stereology 
calculations from histological data would represent a fascinating source 
of further information from ex-vivo material (42, 43). 
 
 
 
1.3 Study design 
 
The aim of the present study was to acquire further information on the 
clinical impact of CD4
+
  T cells with a regulatory phenotype during the 
evolution of a chronic liver disease caused by HCV infection. Both 
peripheral blood and intrahepatic regulatory T cells were investigated, 
the former by flow cytometry analysis of whole blood samples from 
HCV
+
 patients, the latter by immunohistochemical staining of liver 
biopsy samples from the same patients. Along with circulating Tregs, 
the presence of other T cell subsets was assessed, in particular 
CD4
+
CD25low or CD25
neg
 T cells and CD8
+
 T cells. In order to explore 
the clinical state of the disease, serum transaminase levels, viremia 
load, ultra-sound and conventional histology score were evaluated and 
correlated to immunological data. 
 
 
 
1.4 Materials and methods 
 
Patients. Thirty patients with HCV-related chronic hepatitis were 
recruited at the Department of Internal Medicine of P.O. ‘G. Rodolico’, 
Azienda Ospedaliero-Universitaria ‘Policlinico - Vittorio Emanuele’, 
Catania, Italy. They were followed-up by clinical examination, 
measurement of transaminase plasma levels and circulating viral load, 
and ultrasound exploration of the liver. They were also subjected to 
liver biopsies to assess the hepatitis activity and the fibrosis stage. 
The patients included 12 males and 18 females, aged between 39 and 
71 years. The modality of infection was in all cases considered as 
community acquired or undetermined. The HCV genotype was 1b in all 
patients. Only 2 patients were already receiving therapy at the time of 
analysis (Rebetol 1200 mg and PegIntron 135 mg). The controls 
comprised healthy volunteers, 13 males and 7 females, aged between 
28 and 61 years. The study was approved by the local ethics committee. 
Sample and tissue collection. After having obtained informed consent 
from all patients, PB specimens were drawn from the patients and 
control subjects and collected in heparin collection tubes. Needle liver 
biopsies were obtained percutaneously from the patients. 
 
Clinical laboratory analysis. Serum transaminase levels were measured 
by using a Modular Analytics instrument (Roche, Diagnostics, 
Indianapolis, IN, USA). 
 
Histological evaluation. Liver specimens were fixed in 10% neutral-
buffered formalin and processed for embedding in paraffin wax. 
Sections of tissue were stained with hematoxylin and eosin for standard 
light microscopic evaluation using standard methods. The biopsies were 
classified according to the Sheuer score (portal activity/lobular activity 
and fibrosis, from 0 to 4) by an expert pathologist. 
 
Immunohistochemical analysis. Tissue sections (5 μm) were 
microwave-heated for 15 min in 10 mM citrate buffer (pH 6.0) 
(Millipore, Billerica, MA, USA). They were then treated with 1% 
hydrogen peroxide for 15 min and subsequently blocked with pre-
diluted normal goat serum (Santa Cruz Biotechnology Inc., Santa Cruz, 
CA, USA) for 20 min at room temperature. Sections were then 
incubated with anti-Foxp3 antibodies (dilution 1:100, sc-80792; Santa 
Cruz Biotechnology Inc.) and stained with the streptavidin-biotin-
peroxidase complex system (ImmunoCruz™ Staining System; Santa 
Cruz Biotechnology Inc.). Finally, the sections were counterstained 
with Mayer's hematoxylin. Slides were dehydrated, mounted and 
observed by conventional light microscopy. Negative control staining 
was performed by substituting the primary antibody with non-immune 
serum. 
 
Flow cytometry analysis. Whole blood samples were tested for 
leukocytes surface antigens by using FITC-conjugated CD4, PE-
conjugated CD8, and PECy5-conjugated CD25 monoclonal antibodies 
(mAb) (Becton-Dickinson, Franklin Lakes, NJ, USA). The cells were 
then permeabilized with the Foxp3 Buffer Set (eBioscience, San Diego, 
CA, USA), stained with APC-conjugated anti-Foxp3 mAb (Becton-
Dickinson), and fixed in PBS containing 1% of paraformaldehyde. 
Control stainings were performed with the appropriate isotype matched 
antibody. 
For detection of IFN-γ producing cells, 500 μl of whole blood were 
mixed with 500 μl of RPMI-1640 medium with glutamine and 
stimulated with 25 ng/ml of phorbol 12-myristate, 13-acetate (PMA; 
Sigma Chemical Co., St. Louis, MO, USA) and 1 μg/ml of ionomycin 
(Sigma) in the presence of brefeldin (Becton-Dickinson). The cells 
were then incubated in 15 ml tubes at 37˚C in 5% CO2, humidified 
atmosphere for 4 hours. After incubation, surface and intracellular 
staining were performed as indicated above, by using the anti-CD4 
mAb and anti-Foxp3 mAb plus a PE-conjugated anti-IFN-γ mAb 
(Becton-Dickinson); these cells were not stained for CD25, since 
preliminary experiments showed a substantial down-modulation of this 
marker upon treatment with PMA + ionomycin. The samples were 
analysed in a FACSCalibur cytometer (Becton-Dickinson). 
 
Statistical analysis. The percentages of T cell subsets in the examined 
groups were expressed as median and interquartile ranges (IR). The 
statistical significance was assessed by the Mann-Whitney U test. 
Differences were considered to be statistically significant at a level of 
p<0.05. 
 
 
 
 
 
 
1.5 Results 
 
At the histological evaluation executed by an expert pathologist, the 
patients displayed a grading (portal activity vs lobular activity) ranging 
from 1/0 to 3/2; fibrosis was classified from stage 1 to 3. 
 
 
Table 1. Association of Foxp3 expression with Sheuer's score in HCV-affected liver 
sections. 
 
 
The immunohistochemical analysis for Foxp3, detected positive cells in 
11 out of 30 patients (Table I), and showed that Foxp3
+
 cells were 
found among the lymphocytes infiltrating the portal area (Fig. 1). 
 
Figure 1. Representative micrograph of liver section from a HCV affected 
patient. Some lymphocytes are immunolabelled for Foxp3 (arrows) (bar: 60 µm). 
 
 
Transaminase levels were elevated in most patients: 29 and 19 patients 
for alanine transaminase (ALT) and aspartate aminotransferase (AST), 
respectively. The mean ALT serum level was 97.27±32.09 U/l in 
Foxp3
+
 patients vs 127±33.22 in Foxp3
neg
 patients; the mean AST 
serum level was 56.73±28.09 U/l in Foxp3
+
 patients vs 76.21±32.21 in 
Foxp3
neg
 patients. Such a difference between the mean values of Foxp3
+
 
and Foxp3
neg
 patients resulted in a statistical significance for ALT 
(p=0.03) (Table II). 
 
 
 
Table 2: Mean ALT and AST serum concentrations in the patients subgrouped 
by Foxp3 liver immunohistochemistry. The difference between patients with 
Foxp3+ and Foxp3- histology is statistically significant for ALT (p= 0,03). 
 
 
Flow cytometry analysis of the peripheral blood samples showed a 
relative increase in the total amount of lymphocytes in the patients 
compared to the controls; the median percentage of circulating 
lymphocytes was 27.85% (IR 25.82-30.91%) in the patients and 
25.02% (IR 17.08-28.54%) in the controls (p=0.02). Within the 
lymphocyte population, the median percentage of T helper CD4
+
 cells 
was 44.20% (IR 40.06-49.87%) in the patients and 37.20% (IR 31.41-
42.52%) in the controls (p=0.0002); the median percentage of CD8
+
 T 
cells was 38.63% (IR 34.70-39.77%) in the patients and 23.87% (IR 
19.45-25.28%) in the controls (p<0.0001). In CD4
+
 lymphocytes, the 
expression of CD25 distinguished 3 subsets: CD4+CD25
neg
, 
CD4
+
CD25
low
 and CD4
+
CD25
high
. The marker separating the CD25
low
 
and CD25
high
 subset was set at 1 logarithmic decade from the 
CD25
neg
/CD25
low
 cut-off value (Fig. 2a). Within the CD4
+
 cells, the 
median percentages of CD25
neg
, CD25
low
, and CD25
high
 cells were 
47.13% (IR 42.27-60.58%), 49.59% (IR 38.57-53.84%) and 2.47% (IR 
1.67-3.44%) in the patients, and 64.39% (IR 56.71-72.59%), 32.13% 
(IR 24.45-39.42%), and 3.01% (IR 2.32-3.29%) in the controls, 
respectively. The proportions of CD25
low
 cells were significantly higher 
and those of CD25
neg
 cells significantly lower in the patients in 
comparison to the controls (p<0.0001), whereas those of CD25
high
 cells 
were not different between the 2 groups (p=0.08) (Fig. 2b). 
Foxp3 staining was positive but at a low intensity in the CD4
+
CD25
high
 
cells only (Fig. 3), and the Foxp3 mean fluorescence in this population 
was not significantly different between the patients and the controls 
(21.61±9.39 vs. 20.34±10.21, p=0.65). Of note, the proportion of PB 
CD4
+
CD25
low
 cells was significantly higher in the patients displaying a 
positive intrahepatic immunolocalization of Foxp3
+
 cells compared to 
those displaying a negative one (52.87%, IR 41.80-57.73% vs. 41.26, 
IR 37.54- 50.24%; p=0.04) (Fig. 4). The liver biopsies from the 2 
patients receiving therapy were positive for Foxp3. No difference was 
found in the CD4
+
CD25
high
 and CD4
+
CD25
neg
 cell proportions between 
the patients who were Foxp3
+
 and Foxp3neg at a the 
immunohistochemical level. 
 
Figure 2. (a) Representative dot plots from peripheral blood. The cytograms 
show the expression of CD4 and CD25 in the peripheral blood lymphocyte 
population of healthy controls and patients. (b) Bar histogram representing the 
mean percentages of CD25
-
, CD25
low
 and CD25
hi
 cell populations among the 
CD4
+
 cells in peripheral blood lymphocytes, in patients and controls. The 
percentage of CD4
+
CD25
low
 cells is increased in the patients, compared to controls.
 
a
P<0.0001. 
 
 
 
 
 
 
 
  
 
Figure 3. Histograms representing Foxp3 expression intensity among the 
CD25neg, CD25low (empty histograms) and CD25high (filled histograms) cell 
populations in controls (A) and  patients (B). The CD4+CD25high cells are 
Foxp3+ at low intensity, while the CD4+CD25neg and the CD4+CD25low cells are 
Foxp3neg. The fluorescence intensity of the isotype control resulted similar to the 
intensity of the anti-Foxp3 antibody in the CD4+CD25neg and CD4+CD25low 
cells (data not shown). 
 
 
 
Figure 4. Median percentages of CD25
low 
cells in peripheral CD4
+
 T cell 
population
 
in patients subgrouped for liver Foxp3 expression. 
b
P<0.05. 
 
 
After stimulation with PMA and ionomycin, analysis of IFN-γ 
expression showed higher median percentages of IFN-γ+ cells in the 
patients (34.25%, IR 30.85-39.37%) in comparison to the controls 
(17.13%, IR 13.91-20.40%) (p<0.0001); this difference was significant 
in both CD4
+
 (12.61%, IR 10.38-17.42% vs. 4.84%, IR 3.49-7.23%) 
and CD4
neg 
(20.65%, IR 18.71-25.02%, vs 10.51%, IR 7.37-14.89%) 
subpopulations (p<0.0001) (Fig. 5a). After in vitro stimulation, the 
proportion of Foxp3
+
 cells was still not significantly different between 
patients and controls: 1.21% (IR 0.15-2.87%) in the control subjects, 
1.27% (IR 0.24-3.11%) in patients. As expected, Foxp3 was expressed 
only in CD4
+
 cells (data not shown) and double-positive IFN-γ / 
Foxp3
+
 cells were substantially absent (Fig. 5b). 
 
Figure 5. (a) Representative dot plot cytograms showing the expression of CD4 
and IFN-γ after stimulation with 25 ng of PMA and 1 μg of ionomycin, in the 
peripheral blood lymphocyte population, in the healthy controls and in the 
patients. The percentage of IFN-γ+ cells is increased in the patients, both from the 
CD4+ and CD4neg subsets. (b) Representative dot plot cytograms showing the 
expression of IFN-γ and Foxp3 after stimulation with 25 ng of PMA and 1 μg 
of ionomycin, in the peripheral blood lymphocyte population in the patients. 
No populations are identifiable showing a double positivity for the two markers. 
 
 
 
1.6 Discussion 
 
In HCV-associated chronic liver disease, the immune system is unable 
to effectively clear the viral infection, despite the activation of 
humoural and cellular immune responses (44). A number of viral 
factors are involved in this process, such as the ability of HCV to 
modify its surface antigens and to exploit different entry mechanisms to 
infect target cells (45). However, the highly tolerogenic liver 
microenvironment, rich in TGF-β and other profibrotic factors, may 
also inhibit an effective viral clearance by favouring the switch to an 
immune response pattern different from Th1 (46-48). Antiviral CD4
+
 
and CD8
+
 T cell activity is therefore dampened, and these cells are 
likely to either switch to an anergyc state or acquire regulatory 
functions, by producing different cytokine profiles (TGF-β or IL-10) 
and exhibiting different surface markers, like  FOXP3, PD-1 and 
CTLA-4. 
The role played by regulatory T cells in this balance has been discussed 
in previous studies but not clearly defined. In particular, they have been 
shown to be able to impair the response of effector cells to HCV 
antigens and suppress IFN-γ secretion by CD4+ and CD8+ T cells (29-
31); on the other hand, other evidences support the concept that Tregs 
are able to limit the activation-induced cell exhaustion and apoptosis of 
effector cells, thus granting the survival of a memory pool and a long 
lasting immunity (33-35). The role of all the alternatively differentiated 
regulatory lymphocyte subsets is, however, crucial in the final outcome 
of the disease, and further information are needed to clearly identify 
their phenotypical and functional markers. 
In the present study, we tried to correlate the clinical history of the 
disease (by routine clinical monitoring) to the immunological activation 
state in the peripheral blood and within the liver parenchyma. We found 
that the concentrations of serum transaminases were lower in the 
patients displaying Foxp3
+
 cells in the liver inflammatory infiltrates 
than in those lacking these cells, though these results reached the 
statistical significance for ALT transaminase only. Moreover, the 
proportion of peripheral blood CD4
+
CD25
low
 cells, comprising the 
activated-effector compartments of T helper cells, was significantly 
higher in the same patients. 
As expected, we found that the proportions of circulating CD4
+
CD25
low
 
T cells, were increased in the patients compared to the controls. This 
supports their possible involvement in the anti-viral response. In line 
with these findings, the proportions of IFN-γ-secreting cells were also 
increased in the patients, in both CD4
+
 and CD4
neg
 lymphocyte cell 
subsets, as expected in a viral infection. 
By contrast, in our study, the proportions of circulating 
CD4
+
CD25
high
Foxp3
+
 T cells, comprising cells with Treg activity 
(referred to as natural Tregs), were not significantly different in the 
patients and the controls. Similar to the results from other studies (49, 
50), no double-positive IFN-γ+Foxp3+ cells were found in our 
experiments, making it unlikely that Foxp3
+
 cells are simply activated 
effector cells. 
Our findings are in line with the notion that Treg cells help to direct the 
anti-viral response towards the appropriate exogenous targets, limiting 
the damage to tissues due to either exaggerated effector responses, or 
autoreactive responses secondary to molecular mimicry. The notion that 
Tregs infiltrating the liver are associated to a higher presence of 
immunocompetent CD4
+
 cells in the peripheral circulation could offer 
an interesting point of speculation, as this might indicate that natural 
Tregs could also influence the overall homing network of immune cells. 
Moreover, as demonstrated by different authors (34, 35), suppression 
may even prolong the immune response by preventing the massive 
activation and the consequent exhaustion of effector cells. 
Our findings are consistent with the study of Ward et al (51) in the idea 
that the main effect of Treg presence and activation within the liver 
parenchyma during HCV infection leads to a relative reduction in liver 
inflammation while the Treg presence may favour fibrogenesis by the 
production of TGF-β. However, since the correlation with fibrosis still 
remains unclear, analysis of the TGF-β distribution pattern in relation to 
the presence of Foxp3
+
 cells within the liver should be taken into 
consideration as an important goal in further studies. 
It must be underlined that other subsets of Tregs may be involved in the 
disease, but they have not been evaluated in this study since their 
detection is elusive (52); these different subsets (indicated as 
peripherally-induced Tregs), which can be either CD4
+
 or CD8
+
, are 
often Foxp3neg and may differentiate from inappropriately activated 
naive T cells, such as those activated in the absence of costimulatory 
signals or in the presence of high levels of TGF-β or IL-10, which are 
abundant in the liver (53). Alternatively, they may differentiate from 
exhausted effector lymphocytes. 
 
 
 
1.7 Conclusions 
 
In conclusion, it is possible to assume that Treg cells are likely to exert 
a control on HCV-specific cell-mediated immune response. Such a 
control, however, would function as a general mechanism to limit tissue 
damage, and to prevent the exhaustion of effector cells. It is also 
reasonable, that due to their great heterogeneity and plasticity, some 
liver-infiltrating T cells, conditioned by the local cytokine milieu, may 
develop phenotypes which may favour fibrogenesis. Moreover, as a 
result of an aberrant activation mechanism during HCV-associated 
chronic inflammation, some HCV-specific T cells displaying a 
regulatory phenotype, can differentiate in the liver from naïve CD4
+
 T 
cells, being able to inappropriately inhibit the anti-viral immune 
response (4, 52). 
More experience is to be acquired in this direction, with special regard 
to assess new intra-hepatic fibrosis markers that could be able to 
correlate the entity of fibrosis to the presence, activity and persistence 
of cellular actors. Therefore, further studies should be designed by 
recruiting higher number of patients and extending the histological 
analysis pattern in order to acquire more information on Treg activity 
within the liver parenchyma. Of note, stereology quantification studies 
should provide further fascinating source of speculation. 
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2. Phenotypical and functional 
markers in monitoring ex vivo 
expansion of clinical grade Cytokine-
Induced Killers cells (CIK) 
 
 
 
 
 
2.1 Introduction 
 
Cell-based therapies represent nowadays an important and promising 
approach to onco-hematologic diseases and in regenerative medicine. 
Important results have already been obtained, and many others are at 
range. For these reasons this branch of science is currently object of 
intense research. 
In onco-hematology, adoptive cell transfer of ex vivo expanded immune 
cells represents a therapeutic option, thanks to its properties to provide 
protection against post-transplant dangerous viral infections, as well as 
disease relapses, and to favour transplant engrafment (54). Post 
transplant-lymphocyte infusion, also named as donor lymphocyte 
infusion (DLI), finds in the ex-vivo expansion of Cytokine-Induced 
Killer cells (CIK) its most advanced and fascinating strategy to reach 
significant improvement in terms of disease-free survival, while 
reducing the frequency and severity of graft versus host disease 
(GVHD) (55). 
As for other Advanced Therapy Medicinal Products (ATMP, as defined 
by the Regulation N° 1394/2007 of the European Parlament), the 
preparation of CIK cells has to face several bottlenecks for their 
development due to the complexity of the regulatory framework, the 
high costs and the needs for good manufacturing practice (GMP) 
facilities and new end-points for clinical experimentation. The study of 
optimal markers and systems for assessing the functionality of each 
batch of cellular product released is therefore of crucial importance. 
One of the most challenging issues to be solved in the preparation of 
CIK cells is, in fact, a considerable inter-sample variability, which then 
leads to the expansion of products with variable features and properties, 
in terms of total cell number, cell phenotype and functional 
characteristics. Such differences can, in some cases, affect the final 
quality of the product. Thus, several efforts are presently being made in 
order to understand the reasons of this variability, as well as possible 
solutions or systems able to predict in advance the final outcome of the 
product. 
 
 
 
2.2 Scientific background 
 
 
Cytokine-Induced Killer cells (CIK). Cytokine-Induced Killer cells 
(CIK) are a heterogeneous bulk of ex-vivo expanded T lymphocytes. 
Thanks to their peculiar biological features they are considered the 
most promising choice for adoptive immunotherapy. Within the CIK 
culture it is possible to individuate three distinct cells populations: a 
CD3
+
CD56
neg
 cell subset, corresponding to T lymphocytes; 
CD3
neg
CD56
+
 Natural Killer cells, and a hybrid, newly generated 
subset, CD3
+
CD56
+
, which share the properties of both the other 
subsets. 
CIK cells can classically be expanded starting from peripheral blood 
mononuclear cells (PBMC) but may also be generated from bone 
marrow or umbilical cord blood precursors (56). The standard culture 
condition, according to Negrin’s protocol (57), requires three weeks 
with the timed addition of IFN-γ, anti-CD3 (OKT3) antibody and IL-2. 
IFN-γ is only added on day 0; its main activity is to activate the 
monocytes present in the initial bulk culture, which provide both 
contact-dependent (CD58/LFA-3) and soluble (IL-12) crucial signals 
that favour the acquisition of a final Th1 phenotype and the cytotoxic 
power of CIK cells. The anti-CD3 antibody provides mitogenic signals 
to T lymphocytes, subsequently sustained by IL-2 that drives the 
expansion. 
Conventional CD3
+
CD56
neg
 T cells present in the final CIK bulk are 
mostly CD8
+
, though also other, less represented, subsets like CD4
+
 T 
Helper, double-negative CD4
neg
CD8
neg
 and double-positive CD4
+
CD8
+
 
can  be found;  all these subsets display a low cytotoxic ability but a 
high proliferative potential (54). 
Unlike CD3
+
 T cells, CD3
neg
CD56
+
 NK cell subset shows the typical 
features of activated Lymphokine-Activated Natural Killer cells (LAK): 
they display high cytotoxicity in vitro against different cell lines, but a 
short survival when infused in-vivo; in fact, the most important limit 
for the clinical use of pure NK cells is their great dependence on high 
levels of IL-2 that cannot be administered in vivo for long term (58). 
Finally, the CD3
+
CD56
+
 cell subset shows a higher cytotoxicity and 
longer survival capacity compared to Natural Killer cells; CD3
+
CD56
+
 
NKT cells are able to lyse different lines of cancer cells in a NK-like 
manner, and are estimated the major responsible for MHC-unrestricted 
antitumor activity (59). They display basically a terminally 
differentiated, late-effector phenotype (CD45RO
+
 CD27
low
 CD28
low
 
CD62L
neg
 CCR7
neg
). Interestingly, they keep TCR-mediated activation 
and function, and are shown to display an antigen-specific recognition 
and killing of target cells. This property is of particular importance, as it 
has two implications. First, the retaining of a totally functioning TCR 
makes NKT cells less dependent on IL-2 stimuli compared to the high 
levels needed to maintain the activation of NK cells; NKT cells can, in 
fact, be stimulated by antigens or by CD3-targeted antibodies. Second, 
the antigen specificity could further be exploited by expanding antigen-
selected clones of precursors, for example, specific for CMV or other 
opportunistic pathogens that are cause of dangerous, post-transplant 
infections and mortality (54). It is actually well known that, within the 
CIK bulk, NKT cells precursors are CD3
+
 T lymphocytes mainly with a 
naïve, CD4
neg
CD8
neg
 double negative phenotype that eventually, upon 
stimulation, acquire the CD3
+
CD56
+
 phenotype (60). 
 
CIK’s open challenges: clinical translation. An important limitation 
preventing the successful clinical translation of several adoptive 
immunotherapy strategies is the difficulty in obtaining sufficient 
numbers of anti-tumor immune effectors and their short in vivo 
persistence after infusion into the patients. Compared to other adoptive 
immunotherapy strategies, the main functional properties that 
favourably characterize CIK cells are their easy ex vivo expansion, their 
MHC-unrestricted tumor killing ability and their low alloreactivity 
(58). Their reduced alloreactive potential across MHC barriers may 
result in a reduced risk for GVHD if adoptively infused after allogenic 
Hemopoietic Stem Cell Transplant (HSCT). 
The data present in literature, are in favour of a possible use of CIK as 
an alternative to traditional Donor Lymphocyte Infusion (DLI) 
following allogenic HSCT. However, despite in vitro studies showed a 
lower alloreactivity potential for CIK cells, initial clinical trials infusing 
donor CIK cells after HLA identical HSCT, reported a 36% of GVHD 
incidence (61). However, further studies have shown how such 
alloreactivity is basically attributable to the CD3
+
CD56
neg
 fraction of 
CIK's bulk (59). A depletion of this population could therefore lead to a 
reduction of GVHD incidence and strength. This approach might be of 
particular relevance in peculiar HSCT settings with a partial HLA-
mismatch. It is, however, worth to mention that the CD3
+
CD56
neg
 
subset in the CIK bulk is the one that retains the highest proliferative 
potential, and that might therefore represent a source of CD3
+
CD56
+
 
generation in vivo, after infusion.  
CIK cells show particular flexibility in their mechanisms of action, as 
many redirection cytotoxicity experiments show; other intriguing 
perspectives for CIK-based adoptive immunotherapies are given by the 
emerging possibilities to redirect and potentiate their antitumor activity 
with the auxilium of Tumor-Associated Antigens (TAA) – bispecific 
antibodies (62). Recently, CIK-based adoptive immunotherapy has been 
proposed for solid tumors, and clinical trials have started (58).  
In general, the heterogeneity of methods and response evaluation 
criteria make the drawing of definitive conclusions regarding impact on 
survival still early and difficult. Recently, an International Registry on 
CIK Cells (IRCC) has been created, with the aim to collect worldwide 
data on clinical trial results (63). 
 
CIK’s open challenges: batch variability. The standards for optimal 
CIK expansion have been currently successfully validated under Good 
Manufacture Practice (GMP) conditions (56). However, after three 
weeks of culture the expansion rate is reported to be variable, from few 
to more than 1000 fold (64). The reasons of this great variability in the 
expansion rate are still not known, but their understanding would be of 
great importance, as the highest levels of expansions are largely 
feasible for further clinical applications: some batches behave as “poor 
expanders”, and might benefit from additional biological stimuli. 
Soluble factors like Thymoglobulin, IL-1 or IL-7 have been considered 
to be used, as well as the addition of transient allogenic  stimulation 
(delivered by irradiated allogenic PBMC) or the depletion of regulatory 
T cells. Recent studies, in the attempt to shed light on the causes of 
such a high variability, have employed multivariate statistical data 
analysis algorithms, in order to predict the final outcome of a single 
batch (64). 
Moreover, as CIK cells are often expanded starting from PBMC, 
interesting studies have focused the attention on the other populations 
present in the initial PBMC culture, like monocytes and residual 
granulocytes, which could theoretically influence the outcome of CIK 
expansion. Activated neutrophils have been shown to be able to 
increase cytotoxic activity of both NK and T cells (65-69). The role of 
monocytes is, on the other hand, still controversial (70, 71): 
experiments using the transwell system showed that the stimulatory 
effect of autologous PBMC on activated NK cells resides in the CD14
+
 
monocyte fraction; proliferation is in part mediated by humoral factors, 
but is enhanced when NK and monocytes are in direct cell-cell contact 
(70). In other experimental settings, monocytes inhibited the 
proliferation of NK and T cells during IL-2 co-culture for 7, 14, or 21 
days. A reduction in monocytes resulted in a 61-fold expansion of NK 
cells and a 3,7-fold increase of T cells (71). 
Other studies point out how differences in the isolation procedures 
might be responsible for significant functional differences in the final 
cellular product, and delays in processing beyond 8 hours can result in 
early activation of cells, decreased chemokine receptor expression, or 
decreased ability of NK cells to degranulate or secrete cytokines. 
Notably, Seeger and co-workers compared the methods for the 
preparation of bone marrow-derived mononuclear cells (BM-MNC) in 
the REPAIR-AMI and ASTAMI trials (72). In the experiments 
described, the authors found significant differences between the cell 
recoveries obtained using the two products, a difference which was the 
only discernible reason for the differences observed for the number of 
CD45
+
/CD34
+
 BM-MNC, CFU, and MSC (72). 
In line with these findings, the assessment of cell number and viability 
may not entirely reflect the functional capacity of cells in vivo, and 
additional functional testing appears to be mandatory to assure proper 
cell function before embarking on clinical cell therapy trials (73). 
 
 
 
2.3 Study design 
 
Given these open issues, the aim of this preliminary study was to 
acquire further information on the phenotypical and functional features 
of ex vivo expanded Cytokine-Induce Killer cells (CIK), when cultured 
under different experimental variables. In particular, the expansion of 
cells obtained from different density gradient separation reagents was 
tested, by applying different phenotypical and functional tests such as 
total cell count, cell viability, cell separation purity and recovery, cell 
surface flow cytometry staining, calcein-release cytotoxicity assay and 
flow cytometry-based cell cycle analysis. 
 
 
 
2.4 Materials and methods 
 
Sample collection. PBMCs were isolated from 4 buffy coats obtained 
from regular healthy donor whole blood donations. After donation, 
buffy coats were obtained by centrifuging the blood bags in order to 
obtain blood separation into three components: plasma, concentrated 
erythrocytes and buffy coat (containing most leucocytes and platelets). 
The separation procedure was performed to obtain transfusional 
products for clinical use, according to Italian transfusion medicine 
operative standards. The concentrated erythrocytes and plasma 
components contemporarily obtained by the separation were regularly 
employed for clinical purpose. Informed consent about the different 
destination (in vitro use) of the buffy coats was asked for and obtained 
by each donor. No additive amount of blood collection was required, 
compared to a normal blood donation. 
 Isolation of PBMC.  PBMC were obtained by density gradient 
centrifugation of the buffy coats. For the study purpose, 4 different 
density gradient centrifugation reagents were used for each buffy coat 
(Ficoll-Paque PLUS, GE Healthcare, UK; Histopaque – 1077, Sigma-
Aldrich, USA; Biocoll, Biochrom – Merck Millipore, Germany; 
Lymphoprep, Axis-Shield, Norway). 
Pre-isolation leukocyte concentration was assessed by a diagnostic 
emocytometer (ADVIA 120 Hematology System, Siemens, Germany) 
from each buffy coat, in order to calculate the recovery rate of each 
separation reagent. The average leukocyte concentration was over 
25.000 / mm
3
 (range 28-38 x 10
8
). On the basis of preliminary 
experiments, it was established that 4 ml of buffy coat for each isolation 
condition  would have been sufficient to obtain the required amount of 
cells for all experiments. Samples were also analyzed for their 
immunophenotype in flow cytometry prior to separation (see paragraph 
2.4 – Immunophenotypical analysis in flow cytometry). 
A careful comparison of the manufacturer’s instructions of the four 
reagents was conducted prior to set the experiment plan. However, only 
minor differences were found among the recommended operative 
procedures, while all the four manufacturers did not point out strict 
indications about the optimal buffy coat dilution to obtain the best 
separation. For these reasons, we established that a unique operative 
procedure and a dilution of 1:4 were feasible for all the four separation  
reagents. 
For each sample, PBMC were isolated by using all the four separation 
reagents used (as explained above). For each experimental condition, 
two 15 ml polypropylene tubes were firstly filled with 6 ml of density 
gradient separation reagent; subsequently, 8 ml of [1:4-DPBS]-diluted 
buffy coat were added slowly, not to disrupt the separation between the 
two liquid phases. 
Samples were centrifuged at 800 rcf (without brake) for 30 minutes. 
After centrifugation, separated PBMC were recovered from the tubes, 
counted by using Trypan blue exclusion test in a Bürker haematological 
chamber in optical microscopy, washed, analyzed in flow cytometry for 
their phenotype, and resuspended in X-VIVO-10 medium (Lonza, 
Switzerland). 
 Determination of cell recovery, purity and viability. Cell recovery was 
obtained by calculating the percentage from the cell number obtained 
after density gradient separation referred to the number of cells which 
underwent separation. The expected recovery of lympho-monocyte 
population was also calculated, by using the data obtained from a 
diagnostic emocytometers on buffy coat samples (ADVIA 120 
Hematology System, Siemens, Germany ). The purity of the isolated 
population of lymph-monocytes was estimated by flow cytometry 
analysis (see below, Immunophenotypical analysis in flow cytometry). 
Viability of cells was assessed by Trypan blue exclusion test in a Bürker 
haematological chamber in optical microscopy. 
 
CIK cell culture and expansion. PBMC isolated from each separation 
reagent were counted and resuspended in X-VIVO-10 medium at a 
concentration of 5x10
6
 cells/ml. 25 x 10
6
 cells (in 5 ml volume) for 
each condition were then seeded in a different 12,5 cm
2
 culture flask. 
The stimulation schedule, according to Negrin’s protocol, consisted in 
the addition of 1.000 U/ml of IFN-γ (Imukin -  Boehringer-Ingelheim, 
Germany) at day 0, 50 ng/mL of Anti-CD3 (Pure functional grade - 
Miltenyi Biotec, Germany) at day 1, and 500 U/ml of IL-2 (Proleukin, 
Novartis Pharma, Switzerland) at days 1, 3, 7, 10, 14 and 17. Cells 
were incubated for 21 days at 37°C, 5% CO2, in humidified 
atmosphere. Cell concentration was determined at days 3, 7, 10, 14, 17, 
21. After every cell count estimation, incubation was continued at a cell 
concentration of 1x10
6
 cells/ml. No washing step was performed; fresh 
medium was added to lower the concentration. Starting from day 3, 
cells were seeded in 25 cm
2
 culture flasks (1x10
7
 cells in 10 ml 
volume). 
 
Immunophenotypical analysis in flow cytometry. Immunophenotypical 
analysis was performed by using a Beckman Coulter Cytomix FC500 
flow cytometer. Cells were analyzed at day 0 (before and after gradient 
separation), and at days 3, 7, 10, 14, 17 and 21. The fluorescent 
monoclonal antibodies used were directed against CD3 (ECD-
conjugated), CD4(-FICT), CD8(-PECy7), CD56(-PE), CD14(-PE), 
CD33(-APC), CD19(-PECy7) surface antigens. All antibodies were 
provided by Beckman Coulter (USA). 
 
Calcein release cytotoxicity assay. Cytotoxicity of CIK cells was 
assessed at days 7, 14 and 21, by calcein-release fluorimetric assay. 
K562, a human chronic myeloid leukemia cell line was chosen as target 
(K562, subclone ACC10, purchased by DSMZ, GmbH, Germany). 
Briefly, 10
6
 K562 cells were resuspended in 5 ml of 10% FBS RPMI  
medium and incubated with 3,5 μM calcein AM (acetoxymetyl-estere, 
Sigma-Aldrich, Switzerland); after a washing step, labelled cells were 
resuspended in X-VIVO-10 at a concentration of 5x10
4
 cells/ml. 
Effector cells were washed and resuspended at three different 
concentrations (2x10
6
, 1x10
6
 and 5x10
5
 cells/ml) in X-VIVO-10. 
Effector-to-target ratios tested were 10:1, 20:1, 40:1. For the co-
incubation with target cells, a 96-well plate was used: 100 μl of the 
three different concentrations of effectors cells were placed in the wells, 
and 100 μl of target cell suspension were added to reach the required 
E:T ratio. Incubation was performed for 4 hours at 37°C, 5% CO2, in 
humidified atmosphere. All samples were run in duplicate. Four wells 
with target cells alone (100 μl) were used as negative control, to assess 
the basal release; to assess the maximal calcein release, four more wells 
with 100 μl of target cells alone were prepared and 100 μl of 3% 
TRITON 100X were added at the end of incubation. 
After incubation cells were centrifuged and placed in a 
black/transparent bottom 96 well plate. The RFU (Relative 
Fluorescence Units) were obtained by reading the plate with a BF1000 
FluoroCount fluorimeter (λ-excitation 485 nm / λ-emission 535 nm,  
Packard Bioscience, USA). 
 
Cell cycle analysis in flow cytometry. Cell cycle analysis was 
performed in flow cytometry by using the protocol established by 
Carbonari and coworkers in 2008 (19), named FAST (Flow Acetone-
Staining Tecnique). 7-amino-actinomycin (7-AAD) was used as 
intercalating agent (λ-excitation 543 nm / λ-emission 647; 10 μg/ml 
final concentration). 
Collected data were analyzed by the Multiple AV software (Phoenix 
Flow Systems, San Diego, CA). 
 Fold expansion estimation. Fold expansion estimation was obtained by 
multiplying the number of cells counted at every checkpoint (day 0, 3, 
7, 10, 14, 17, 21) for the number of cells obtained at the preceding 
checkpoint. Noteworthy, as the starting concentration (day 0) was 5 x 
10
6
 cells/ml, the number of cells at day 3 was divided by 5, to 
normalize the starting count at 1 x 10
6
 cells/ml. 
 
Statistical analysis. Statistical analysis of collected data was performed 
by using the Prism 5 software (Graphpad, USA). The difference among 
the data from the four different separation reagents were tested for 
significance. ANOVA test was used, along with Tukey’s post-test for 
multiple one-to-one comparisons among the separation reagents. p 
value <0,05 was considered as statistically significant. Data are 
expressed as mean ± sd. 
 
 
 
2.5 Results 
 
Cell recovery, purity and viability. The overall recovery estimation 
from the four experimental conditions showed that Ficoll-Paque PLUS 
(GE Healthcare) exhibited a significantly lower recovery rate (54,3± 
3,3%); the other reagents did not show statistically significant 
differences (Fif. 6/A). The expected recovery of lympho-monocyte 
population ranged from a minimum of 96,3% (Sample 3 / GE-
Healthcare) to a maximum of 99,9% (Sample 1 / Axis-Shield), without 
significant differences (data not shown). Purity of the isolated lympho-
monocyte populations was inversely correlated to the presence of 
residual granulocytes and proved to be significantly lower in the cell 
suspension obtained from Axis-Shield reagent (Fig. 6/B). Although 
without statistically significance, the highest purity was observed on the 
GE-Healthcare-derived cell suspension. Cell viability was comprised 
from a minimum of 93,5% (Sample 2 / Biochrom) to a maximum of 
98,6% (Sample 3 / Axis-Shield) without significant differences (data 
not shown). 
 
 
 
Fig 6. Recovery and purity rate of the four different separation reagents 
(Data are expressed as mean ± standard deviation). 
 
 
Phenotypical features of the isolated population. Regarding the initial 
presence of monocytes and B lymphocytes, no statistically significant 
differences were observed among the four reagents. Table 3 shows the 
mean percentages of B cells and monocytes in the cell suspensions 
obtained after the density gradient separation performed by using the 4 
different reagents. By the course of the culture their percentage 
dramatically fell down, as well as the one of granulocytes. At the third 
day of culture the percentage of granulocytes and monocytes became 
undetectable in all cultures (data not shown), while B cell percentage 
were detectable until day 14 (Fig. 7). 
 
 
 
Table 3. Percentages of contaminant populations after density gradient 
separation. 
 
B lymphocytes Monocytes Granulocytes
GEH 6,6 ± 2,9% 8,3 ± 2,8% 1,9 ± 0,5%
SIG 7,0 ± 2,7% 9,3 ± 3,6% 2,0 ± 0,7%
BIO 5,9 ± 2,0% 8,8 ± 1,9% 2,9 ± 0,6%
AXS 7,7 ± 3,0% 9,4 ± 2,9% 5,6 ± 1,4%
Percentages of unwanted cells after density gradient 
separation (day 0; values are indicated as mean ± s.d.)
Figure 7. Percentage of B cells in the expanding culture. 
 
 
As expected, the starting T cell population was constituted by a 
majority of CD3
+
CD56
neg
 cells, whereas cells with Natural Killer 
phenotype (CD3
neg
CD56
+
) and naive 'double-positive' CD3
+
CD56
+ 
cells 
represented minor populations. No statically significant differences 
were detected among the cell suspensions obtained from the four 
reagents. The percentages of the different cell populations along the 
culture days are shown in Figure 8 and 9. 
 
CIK expansion. Figure 8 shows the growing curve of CD3
+
CD8
+
 and 
CD3
+
 CD4
+
 cells during the culture days under the four different 
experimental conditions; figure 9 shows the growing curve of CD3
-
CD56
+
 and CD3
+
CD56
+
 cells; table 4 shows the mean percentages of 
the these populations (± s.d.) at the end of the culture, under the four 
different experimental conditions.  
 
 
 
 
 
 
 
 
 Figure 8. CD8
+
 and CD4
+
 T cell subset growing curve along CIK expansion. 
 
 
 
 
Figure 9. CD3
neg
CD56
+
 and CD3
+
CD56
+
 cell growing curve along CIK 
expansion. 
 
 
 
 
 
Table 4. Percentages of cell subsets constituting CIK bulk at the end of the 
culture. 
 
 
CD3+CD8+ CD3-CD56+ CD3+CD56+
GEH 75,3 ± 8,4% 5,2 ± 2,1% 34,0 ± 16,1%
SIG 74,9 ± 9,5% 4,4 ± 2,0% 34,5 ± 12,4%
BIO 72,2 ± 10,6% 6,4 ± 1,9% 28,9 ± 14,4%
AXS 73,6 ± 8,8% 5,2 ± 2,0% 35,3 ± 15,8%
Percentages of cell subsets constituting CIK bulk at the end
of the culture (day 21; values are indicated as mean ± s.d.)
CD3
+
CD4
+
 T helper cells show an initial increase due to the stimulation 
mediated by IFN-γ, anti-CD3 and IL-2. However, on further days, their 
percentage shows a decrease due to their incapacity to proliferate in the 
presence of IL-2 only. 
At day 21 of the culture, the major population is represented by 
CD3
+
CD8
+
 T cells, a variable but significant portion has shown to be 
also CD56
+
 (data not shown). The culture derived from Biochrom 
separation reagent shows lower percentage of CD3
+
CD56
+
 cells: 
statistical analysis reveals that this difference is significant in 2 sample 
out of 4 (p<0.05). The growing curve of CD3
+
CD56
+
 cells obtained 
from Biochrom reagent showed also a deceleration starting from day 17 
(figure 9). 
The percentage of CD3
neg
CD56
+
 Natural Killer cells showed no 
statistical significance (figure 9). 
 
Cytotoxicity assays. Cytotoxicity of CIK cells increased from day 7 to 
day 21, in all experimental conditions. The increase in cytotoxic 
activity was more dramatic between day 7 and day 14. Although the 
data obtained did not reach a statistical significance, the CIK population 
obtained from Biochrom reagent showed a lower mean cytotoxicity 
compared to the others (figure 10). 
 
 
Figure 10. Cytotoxicity assay across culture days (E:T 10:1). 
 
 
 
Cell cycle, and fold expansion. Cell cycle analysis revealed a 
progressive decrease of cells undergoing active DNA synthesis along 
the culture (Figure 11), showing that the the highest proliferation 
occurred during the first two weeks of culture. No significant difference 
could be appreciated among the four experimental conditions.  
Fold expansion ranged from a minimum of 14,9 (Sample 1/Biochrom) 
to a maximum of 221,7 (Sample 3/GE); the mean values did not show 
significant difference (Figure12). 
 
 
Figure 11. Analysis of cells cycle along culture days. 
 
 
 
Figure 12. Expansion curve and mean fold expansion values. 
2.6 Discussion 
 
The high variability of CIK expansion results, in terms of fold 
expansion and cell functionality, render CIK protocol translation into 
clinical settings difficult. Despite CIK expansion protocol has already 
been validated under Good Manufacture Practice (GMP) conditions 
(56), further optimizations in order to reduce such variability are still 
possible; thus, further validations studies should be programmed. 
The application of functional tests in the present study, to monitor 
different features of CIK cells along their expansion, has revealed how 
minor variables, even the first isolation step, can lead to significant 
differences in terms of composition and functionality of expanded cells. 
The use of density gradient separators is a very common laboratory 
practice, though the choice of the reagent to be employed is often a 
minor issue, mainly dependent on economical matters. However, as 
also previous studies have stated, processing variations might be able to 
completely change the conclusion of a study (73); great attention 
should therefore be paid especially when the complete functional 
capacity of cells is essentially required. 
In our preliminary study, despite the number of the samples collected 
was low, a statistically significant correlation could be established for 
some critical aspects, such as post-separation cell recovery, purity, and 
population doubling. For other data sets, such as percentage of 
CD3
+
CD56
+
 cells along the culture days, CIK cell fold expansion and 
cytotoxicity, although a statistical significance was not reached, a clear 
and univocal information emerged, suggesting the idea that a higher 
sample number could provide the statistical confirmation. In particular, 
GE-Healthcare reagent granted the strictest selectivity (lowest recovery 
rate and lowest residual contaminants), but its performance was among 
the highest as for population doubling and citotoxicity. On the other 
hand, Biochrom reagent performance often  tended to be at the lowest 
levels, in terms of fold expansion and citotoxicity; moreover, cells 
isolated by this reagent saw a decrease in their expansion starting from 
day 17. As the number of precursors was the same for all experimental 
conditions and no exuberant  numbers of contaminant cells could be 
detected after using Biochrom reagent compared to others, it is possible 
to postulate that this reagent has a negative impact on the functionality 
of stimulatory membrane receptors. This is particularly important when 
the in vivo functionality is considered; it is worth to remember that in 
vitro cytotoxicity against K562 cell line depends greatly on the activity 
of CD3
neg
CD56
+
 Natural Killer fraction of CIK cells; in vivo, on the 
contrary, the cytotoxic activity seems to be dependent mostly on the 
number and functionality of CD3
+
CD56
+
 population: the in vivo impact 
of a separation reagent which grants suboptimal expansion and 
longevity of the CD3
+
CD56
+
 fraction could therefore negatively 
influence the functional response of the final cellular product. A 
technical consequence of this outcome is finally that alternative systems 
for assessing citotoxicity, more sensible and non uniparametric, such as 
flow cytometry based assays, should be taken as an important option, as 
they could more faithfully estimate and foresee the real in vivo 
functionality of cells. 
 
 
 
2.7 Conclusions 
 
In conclusion, the ex vivo expansion of Cytokine-Induced Killer cells 
(CIK) for clinical applications is affected by a high inter-sample 
variability of cell functionality which delays the entry of this product 
into clinical settings. Further validation studies are therefore necessary 
in order to understand the causes of such a high variability. Of note, 
different processing variations such as the use of a specific density 
gradient separation reagent, could play a role in the suboptimal level of 
cell expansion and citotoxicity, as they could be able to influence the 
crosstalk among the different cellular subsets present in the CIK bulk. 
The use of appropriate phenotypical and functional tests used in 
combination to assess cell behaviour during the entire expansion 
process could be able to provide the scientist the right clues to orient 
the optimization process. 
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3. Nectin-like-5 expression correlates to 
malignant phenotype 
in cutaneous melanoma 
 
 
 
 
 
3.1 Introduction 
 
Malignant melanoma arises from the transformation and proliferation 
of melanocytes that are normally found in the basal cell layers of 
epidermis. It is the most deadly form of skin cancer, deriving from de 
novo melanocyte transformation in 75% of the cases and from 
preexisting nevi in 25% of the cases. Melanoma accounts for less than 
5% of skin cancers but is responsible for 80% of skin cancer related 
deaths. 
The pathogenesis of melanoma is a complex phenomenon in which 
environmental, genetic, and host factors are involved. Several studies 
have shown how alterations in the expression of molecules involved in 
motility and cellular crosstalk are one of the most important 
pathological events leading to the development of melanoma tumors. 
From these events depend the ability and the propension of transformed 
cells to give metastasis. The list of the effectors includes cell-cell and 
cell adhesion molecules, matrix-degrading enzymes, cytokines and 
other cleavage-derived motility factors, growth factors and their 
receptors. Malignant melanoma is an excellent model for studying these 
molecules, due in part to a sequential series of defineable stages. As the 
malignant phenotype of melanoma cells changes from the noninvasive 
radial growth phase to the vertical growth phase, which has high 
metastatic potential, the repertoire of the cellular adhesion molecules 
changes. 
Recently, a growing interest has been focused on new cellular crosstalk 
molecular systems, such as the lectin families. In particular, Nectin-like 
molecule 5 (Necl-5), also known as Polio Virus Receptor (PVR) or 
CD155, has come to the first line of scientific interest thanks to its 
multiple functions. As a nectin molecule, its primary function seems to 
be the regulation of cell-cell cross talk. Several studies have 
demonstrated that Necl-5 overexpression in cancer cells is essential for 
migration, invasion, proliferation and metastasis formation abilities, but 
there is not yet enough evidence about the possible use of this molecule 
as a biomarker, nor as a target for possible therapeutic approaches. 
 
 
 
3.2 Scientific background 
 
Melanoma overview. Cutaneous metastatic melanoma (CMM) is the 
most deadly form of skin cancer, deriving from de novo melanocyte 
transformation in 75% of the cases and from preexisting nevi in 25% of 
the cases. Melanoma accounts for less than 5% of skin cancers but is 
responsible for 80% of skin cancer related deaths. Melanoma incidence 
in Caucasian population has increased dramatically worldwide during 
the past several decades (75). Melanoma is a cancer with a relatively 
good prognosis when diagnosed early at a cutaneous localized stage. 
Patients with thin lesions can usually be cured with surgical excision. 
Their 5-year survival rate ranges from 90% to 100%. However, the 
prognosis worsens the deeper the lesion extends below the skin, 
because of melanoma’s propensity to invade and to form metastasis. 
Individuals with thick melanomas have an increased risk to develop 
lymph node and visceral metastases. Metastatic melanoma cannot be 
completely removed by surgery and metastatic cells display extreme 
resistance to all types of treatment. Patients with metastatic melanomas 
have a median survival rate that typically ranges from six to ten months 
(76). 
The genesis of melanoma is a complex phenomenon in which 
environmental, genetic, and host factors are involved. Recent data 
reveal that melanomas are heterogeneous tumors, harboring various 
genetic alterations, developing at different body sites and on sun-
exposed and non sun-exposed regions, suggesting that melanoma arises 
from divergent causal pathways. Curtin and coworkers proposed a 
molecular classification based on the sites where melanoma occurs, the 
genetic alterations and the sun exposure history (77). 
Malignant melanoma arises from the transformation and proliferation 
of melanocytes that are normally found in basal cell layer of the 
epidermis. Tumor growth can be biphasic or monophasic (78).  The 
biphasic pattern consists of a horizontal or radial initial growth phase 
(RGP) followed by a subsequent vertical growth phase (VGP) 
corresponding to the infiltration of the dermis and hypodermis. The 
monophasic growth pattern of melanoma consists of pure vertical 
growth mode. When the lesion enters the vertical growth phase, the 
repertoire of adhesion molecules changes as the tumor enters the dermis 
and acquires the capacity to metastasize. Genetic alterations including 
inactivation of the INK4a/ARF melanoma susceptibility locus, 
activating mutations in RAS/B-RAF oncogenes, alterations/loss of 
PTEN, p53 mutations, and CDK4 mutations occur early during 
melanoma development (79, 80). 
 
Cellular crosstalk in melanoma. In normal skin, melanocytes are found 
as single cells scattered among keratinocytes at the epidermal-dermal 
border. Melanocytes form both functional and structural contacts with 
keratinocytes, the latter having been shown to control proliferation, 
differentiation and the expression of cell surface molecules on 
melanocytes. Several studies on melanoma metastasis and melanoma-
derived experimental cell lines with different metastatic potential have 
shown how the alterations of the expression of the molecules involved 
in the regulation of motility and cellular crosstalk are one of the most 
important pathological events that characterize the development of 
melanoma tumors; in fact, the ability and the propension of transformed 
cells to form metastasis depend from these critical events. The list of 
the effectors includes cell-cell and cell adhesion molecules, matrix-
degrading enzymes, cytokines and other cleavage-derived motility 
factors, growth factors and their receptors (81). In particular, authors 
have identified in the downregulation of E-cadherin and upregulation of 
N-cadherin adhesion proteins crucial events leading to the development 
of locally invasive and metastatic malignant melanoma phenotypes 
(82). It is actually well known that during melanoma progression the 
loss of E-cadherin expression disrupts normal homeostasis in the skin 
by freeing melanoma cells from structural and functional regulation by 
keratinocytes. The loss of functional E-cadherin, paralled by a gain in 
N-cadherin function mediates homotypic interaction between 
melanoma cells, thus facilitating gap-junctional formation with 
fibroblasts and endothelial cells and promoting melanoma cell 
migration and survival. In addition, loss of E-cadherin may affect the β-
catenin/wnt signaling pathways (leading to c-myc and cyclin D1 
activation), resulting in deregulation of genes involved in growth and 
metastasis (82, 83). Downregulation of the original matrix receptors, 
such as α5β1 fibronectin-receptor, and various laminin/collagen IV 
receptors, such as α6β1 or α6β4, have also been found in melanoma 
cells (84); the altered expression of these molecules involved in the 
motility process and cellular crosstalk have been found to determine 
rapid changes in adhesion/detachment cycles of transformed cells.  
Melanoma progression is further associated with activation of matrix 
metalloproteinases such as MMP-2 (85), and with deregulated 
expression of the intercellular adhesion molecules such as ICAM-1 
(CD54) (86), and MCAM/MUC18 that mediates homotypic and 
heterotypic adhesion between melanoma cells and endothelial cells 
(87). Other cellular adhesion molecules of the cadherin, integrin, and 
immunoglobulin superfamilies are also important to both growth and 
metastasis of melanoma. Malignant melanoma is an excellent model for 
studying these molecules, due in part to a sequential series of definable 
stages. As the malignant phenotype of melanoma cells changes from the 
noninvasive radial growth phase to the vertical growth phase, which has 
high metastatic potential, so does the repertoire of the cellular adhesion 
molecules expressed on the cells surface. 
 
CD155. Recently, a growing interest has been focused on new cellular 
crosstalk molecular systems, such as the lectin families. In particular, 
Nectin-like molecule 5 (Necl-5), also known as Polio Virus Receptor 
(PVR) or CD155, has come to the first line of scientific interest thanks 
to its multiple functions (88). As a nectin molecule, its primary function 
seems to be the regulation of cell-cell and cell-matrix cross talk. 
Evidences support the concept that this molecule can exert a role in 
driving the cell motility through the matrix, and that it is basically 
involved in cell migration, as it has been shown how it is preferentially 
localized at the leading edge of moving cells and promotes cell 
movement and proliferation (89). It has been shown to enhance cell 
movement and proliferation cooperatively with activated integrin αvβ3 
and growth factors receptors, such as Platelet-Derived Growth Factor 
(PDGF) receptor (90). When moving cells come into contact with each 
other, the initial cell-cell contact that occurs via the trans-interaction of 
Necl-5 with Nectin-3 and integrin αvβ3 remains active. However, the 
trans-interaction of Necl-5 with Nectin-3 is transient. Nectins and 
cadherins interact with each other to form adherence junctions once 
Necl-5 is endocytosed, and consequently disappears from the cell 
surface (91). Thus, the expression of Necl-5 is downregulated when 
cultured cells become confluent, resulting in the suppression of cell 
movement and proliferation (92). 
Aside with this primary function it has been outlined how Necl-5 can 
also function as a ligand of Natural Killer cell activating receptors 
DNAM-1 and CD96 (Tactile). This class of activating receptors are 
able to bind to molecules of the nectin famliy, like Necl-5 or Nectin 12, 
and mediate activatory signals to NK cells (93). Such a second function 
of Necl-5 is in line with the concept that its primary function is 
involved in eliciting cell migration and motility. NK cells, in fact, are 
known to be induced to attack cells with a high motility attitude, when 
they do not express adequate levels of MHC molecules. 
Several studies have demonstrated that Necl-5 overexpression in cancer 
cells (both of epithelial and neurological origins, like colorectal 
carcinoma (94), breast carcinoma, neuroblastoma and glioblastoma (95, 
96) is significant in their migration, invasion, proliferation and 
metastasis formation abilities (97, 98). Further studies could add 
knowledge on the possibilities to exploit this molecule as a target for 
therapeutic approaches or as a marker for cancer early detection and 
follow-up. 
 
 
 
 
 
 
 
3.3 Study design 
 
The aim of the present study was to investigate on the possible use of 
Necl-5 as a marker for melanoma progression, by comparing its 
expression levels in healthy skin samples, as well as in benign nevi and 
in melanoma biopsies. Cell lines have also been tested for the 
expression of Necl-5. Different laboratory techniques have been used. 
 
 
 
3.4 Materials and methods 
 
Tissue samples and patient characteristics. Archival paraffin tissue 
section of 91 melanocytic lesions excised between 2006 and 2010 were 
retrieved from the Department of Pathology at Vittorio Emanuele 
Hospital, Catania, Italy. The collection and storage of samples were 
performed according to local ethical guidelines. Institutional review 
board approval was obtained for this study. There were 59 CMM, 
including 10 melanoma in situ, 12 metastatic malignant melanoma, 
randomly chosen for the study (among which 8 subcutaneous 
melanoma lesions and 4 regional lymph node metastases), 20 BMN, 10 
normal skin adjacent to different tumour masses. Clinical staging of 
CMM was performed on a pathological basis according to the new 
American Joint Committee on Cancer 2001 classification system. 
Diagnosis and staging of BMN had been performed on the basis of 
clinical, histopathologic findings. All sections of CMM were superficial 
spreading melanoma (SSM) and nodular melanoma (NM), at different 
stages (Clark’s level I to III). Localization of the primary melanoma 
were grouped in three classes: head/neck, trunk, extremities. We 
stratified CMM by the Breslow tumor thickness as thin (≤1mm) and 
thick (>1mm). Specimens were fixed in neutral 4% buffered 
formaldehyde for a minimum of 24h and subsequently embedded in 
paraffin. The clinicopathological features of 91 melanocytic lesions are 
summarized in Table 5. 
 
Cell lines and culture conditions. Human epidermal melanocyte 
(NHEM) cell line and melanoma cell lines (WM35, A375, M14) were 
maintained in Melanocyte Growth Medium (Lonza, Walkersville, USA) 
and RPMI medium (Gibco, Life Technologies Inc., Milan, Italy), 
supplemented with 2 mmol/l L-glutamine, 100 IU penicillin and 100 
μg/ml streptomycin and 2% heatinactivated fetal calf serum (Gibco Life 
Technologies Inc.), respectively. All cell lines were cultured at 37°C in 
5% CO2 atmosphere at constant humidity and passaged twice a week. 
Melanocytes and melanoma cells were grown to subconfluency, 
harvested and subjected to downstream analysis. 
 
RT-PCR analysis. Total cellular RNA was extracted from cultured cell 
lines with Micro-to-Midi total RNA purification system (Invitrogen, 
Milano, Italy) according to the manufacturer’s instructions. Reverse 
transcription was carried out by using M-MLV reverse transcriptase 
(Invitrogen) and random primers (Invitrogen). Semiquantitive PCR was 
carried out by applying standard conditions. The following primers 
were used (5’→3’): CD155- sense: TATCTGGCTCCGAG-
TGCTTGCC; CD155 antisense ACGACGGCTGCA-AAAGTGGCG; 
glucose-6-phosphate dehydrogenase (G6PD) sense: ACG-
TGATGCAGAACCACCTACTG; G6PD antisense: 
ACGACGGCTGCAAA-AGTGGCG. For quantitation, gels were 
scanned, and the pixel intensity for each band was determined using the 
Image J program and normalized to the amount of G6PD. 
 
 
 
 
Table 5. Socio-demographic and clinical features of patients with melanoma 
and benign nevi. 
 
 
Immunoblot analysis. Immunoblot analysis was performed as described 
by Merrill and coworkers (99). Antibodies included anti-CD155 (ab 
103630, Abcam, Cambridge, UK) and anti-β Actin (Sigma-Aldrich). 
CD155 antibody binding was detected by streptavidin-horseradish 
peroxidase complex (Roche, Indianapolis, IN) and visualized by using 
enhanced chemiluminescence substrate (Amersham Life Science, 
Piscataway, NJ, USA). β Actin was used as an internal loading control. 
 
Flow cytometry analysis. Cell lines were washed in PBS. Cell 
suspensions were stained with phycoerythrin-conjugated mouse IgG1 
isotype control and mouse IgG1 anti-CD155 (Bioscience, USA). Cells 
were analyzed by using a FACScalibur flow cytometer (Becton 
Dickinson, USA). After gating cells on a forward scatter/side scatter dot 
plot window on linear scale, fluorescence intensity of PE-conjugated 
isotype control and anti-CD155 labelled cells were analyzed in 
histograms on FL2 channel with logarithmic scale. 
 
siRNA gene-expression silencing. A double stranded siRNA 
oligonucleotide targeting CD155 (5’-
CAACUUUAAUCUGCAACGUdTdT-3’) was chemical-ly synthesized 
(Dharmacon Research) and transfected into WM35, A375 and M14 
cells using Oligofectamine (Invitrogen), following manufacturer’s 
instructions by using 200 nM siRNA per 10 cm dish. Cells were 
incubated with siRNA in OptiMEM (Invitrogen) for 6 hrs after which 
time normal growth media was added. Cells were then incubated for 72 
hours to achieve >80% knockdown of CD155. Control cells were 
transfected with a scrambled siRNA oligonucleotide at matching 
concentration. After transfection, cells were harvested and subjected to 
invasion assay. 
 
Tumor invasion assay. In vitro invasion assay was done by using a cell 
invasion assay kit based on the manufacturer’s protocol (Chemicon, 
Billerica, MA). Control cells and siRNA-treated cells were trypsinized 
and used for the invasion  assay. 
 
Immunohistochemistry. Immunohistochemical staining of NECL-5 was 
performed according to standard protocols by using anti-CD155 
antibody (ab60115, Abcam, Cambridge, UK). Detection of primary 
antibody was performed by using the streptavidin–biotin–peroxidise 
complex system (Santa Cruz Biotechnology Inc., Santa Cruz, CA), 
according to manufacturer’s instructions. The detection was carried out 
using Histostain-Plus Kit (Zymed, South San Francisco, CA). AEC (3-
amino-9-ethylcarbozole) was used as a chromogen. Negative control 
experiments were performed as above described. Detection of YY1 was 
performed by using Sigma Aldrich HPA001119  antibody, according to 
the manufacturer’s instructions. 
 
Image analysis. Immunolabelled and sampled tumor sections were 
observed using a Leica DMRB microscope (10× and 40× 
magnification) (Leica, Wetzlar, Germany), the images were 
photographed with a Canon G-9 camera (Canon, Japan) and analyzed 
using Image J software. Four randomly chosen fields of view were 
assessed in melanoma biopsies and in cell lines. A section was 
considered negative or positive according to the absence or presence of 
cytoplasmic staining. Immunoreactivity was assessed by the amount of 
positive malignant cells in the area. We used a staining index (SI; 
values 0-16) with the following formula: SI = immunostaining intensity 
x positive area, where intensities were scored semiquantitatively as 
follows: 4+ = very strong; 3+ = strong; 2+ = moderate; 1+ = weak; 0 = 
negative. Positive areas were defined as the epithelial area that showed 
positive malignant cells for NECL-5 immunoreactivity and was graded 
on an arbitrary scale as 0 = absent; 1+ = less than 25%; 2+ = 25% to 
50%; 3+ = 51% to 75%; 4+ = more than 75%. The distribution of 
staining was classified as focal or diffuse. Localization of staining 
(membranous or cytoplasmic) was also recorded. Scoring was based 
upon the consensus of three histopathologists. 
 
Gene expression datasets. Computational evaluation of NECL-5 has 
been performed by Oncomine software. Differential mRNA expression 
analyses among normal skin tissue versus benign melanocytic skin 
nevus (BMN), BMN versus cutaneous malignant melanoma (CMM) 
and CMM versus metastatic melanoma were explored in 3 datasets 
showing statistical significance less than 0.05 (p<0.05) (100-102). 
Statistical analysis was accomplished through use of ONCOMINE 
algorithms. Haqq Melanoma Dataset was excluded from the study as a 
different microarray platform has been used by the authors (103). Fold 
change values were considered for this analysis. Correlation between 
NECL-5 and Yin Yang 1 (YY1) transcript levels was analyzed 
according to Oncomine software in the Xu Melanoma Dataset (102). 
 
Statistical analysis. Statistical analyses were performed using SPSS for 
Windows. Comparison of socio-demographic and clinical 
characteristics of benign nevi and melanoma patients was performed 
with the χ2 test. Normally distributed data were expressed as media ± 
SE and non normally distributed data were expressed as median 
(range). To correlate NECL-5 staining index and clinic-pathologic 
features χ2 square test was applied. Additionally, the correlations 
between NECL-5 expression in melanoma sections and Breslow 
thickness were assessed by Spearman rank correlation. For 
semiquantitative RT-PCR analysis, statistics was performed by using 
the unpaired Student’s t test. The statistical differences of NECL-5 
expression level between primary and metastatic melanoma samples 
were calculated by Student t test or one-way analysis of variance 
(ANOVA). Differences were considered to be statistically significant at 
a level of p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5 Results 
 
Immunohistochemistry. Immunohistochemistry evaluation showed that 
NECL-5 protein is expressed in all melanoma cell lines. In detail, 
NECL-5 immunolabelling was mainly localized at both extracellular 
and intracellular level of WM35, A375 and M14 cells and a stronger 
immunolabelling was observed in metastatic cell lines (Figure 13). 
 
 
 
Figure 13. Immunolabelling for Necl-5 protein in normal melanocytes 
(NHEM) and melanoma cell lines, WM35, A375 and M14. In NHEM (a) the 
immunostaining is almost absent. WM35 (b), A375(c) and M14 (d) cells are labeled 
for Nelc-5. The protein is mainly localize at the cell membrane and at the cell 
leading edge (bar: 50 µm). 
 
IHC evaluation of NECL-5 was also performed in 20 benign nevi and 
71 melanoma specimens, including 12 metastatic melanoma (Figure 
14). Normal skin tissues showed no immunostaining (Figure 14a) 
whereas a positive immunostaining was in CMMs specimens (Figure 
14c and 14d). The immunopositivity for NECL-5 was also significantly 
different between the benign nevi (Figure 14b) and malignant lesions 
(primary and metastatic melanomas; Figure 14c and 14d). 10 of 20 
(50%) benign nevi samples had minimal weak immunostaining of 
NECL-5. It was mainly detected in the outer zones of the rows of 
melanocytes and, almost absent, in cell-cell contacts between 
melanocytes (Figure 14b). In 3 nevi, NECL-5 immunostaining was 
present in the epidermis and upper dermis. Almost 91.5% of all 
melanoma specimens (primary and metastatic melanomas) showed an 
enhanced NECL-5 immunoreactivity (Figure 14c and 14d) when 
compared to NECL-5 immunoreactivity of benign nevi (14b; 
p<0.0001). In primary melanoma, NECL-5 staining was detected in 
cytoplasm and/or membrane of cancer cells. Immunoreactivity of 
NECL-5 was observed to be higher, within tumor cells, in metastatic 
melanomas than in primary melanoma (p<0.001). A strong reactivity 
for NECL-5 was observed in papillary dermis, and a variable reactivity 
in reticular dermis or around blood vessels (Figure 14d). As shown in 
Figure 14e and 14f, NECL-5 expression is higher in melanoma sections 
with thickness > 1 mm in comparison with those with thickness ≤ 1 
mm. 
 
 
 
 
Figure 14. Representative sample of NECL-5 histological staining of skin 
lesions. (a) normal skin; (b) nevus; (c, d, e and f) malignant melanoma. 
 
 
The immunoreactivity was represented by the assignment of staining 
index (SI), in which the intensity of immunostaining was multiplied by 
the extent of positive area in the tissue samples. The mean staining 
index ± SE for benign nevi was 2.3 ± 0.51; it was 7.95 ± 0.45 and 12.6 
± 1.58 for primary and metastatic melanoma samples, respectively. In 
this analysis, primary and metastatic melanoma showed significantly 
higher level of NECL-5 expression than nevi (p<0.0001). As shown in 
the Table 6, 8 of 20 (40%) benign nevi were negative, only 2 of 20 
(10%) displayed moderate and 10 of 20 (50%) had weak NECL-5 
staining. We found that 51% of primary melanomas samples showed 
strong (30 of 59 cases) or 27% moderate (16 of 59) or  12% weak (7 
out of 59) immunostaining, whereas 6 of 59 (10%) were negative and 
those negative samples were all melanoma in situ. NECL-5 was 
immunohistochemically detected in all melanoma metastases. Among 
12 metastasis, 8 (67%) showed strong staining, 3 of 12 (25%) moderate 
and 1 of 12 (8%) had weak staining intensity. 
We further examined a possible correlations between NECL-5 
expression profiles in melanoma samples with their clinicopathologic 
features. Our analysis in melanoma tissue sections revealed that NECL-
5 expression was strongly correlated to lymph node involvement (p = 
0.009) and Breslow thickness (p = 0.004). As expected, the comparison 
between the group of melanoma sections with thickness > 1 mm and 
those with thickness ≤ 1 mm evidenced that NECL-5 immunoreactive 
scores were higher in thick (score: mean 10.53 ± 0.74, P = 0.003) than 
in thin melanomas (score: mean 7.51 ± 0.59). In particular, 26 out of 32 
(81.2%) thick melanoma displayed a staining of 4 +;  9.4% (3 of 32) 
had 3+ and 9.4% (3 of 32) showed 2+, while, 28.2% (11 of 39) thin 
melanoma had 4+, 25.6% (10 of 39) had 3+ and 46.1% (18 of 39) 
showed 2+. NECL-5 immunoscore was directly correlated to Breslow 
thickness (r = 0.59, p = 0.0001). These observations suggested a 
correlation between increased NECL-5 expression and clinical 
progression in melanoma. However, no evident correlations were 
observed between NECL-5 expression profiles and other 
clinicopathologic features, including age, sex, type of primary 
melanoma (superficial-spreading melanoma and nodular melanoma), 
Clark’s levels and ulcerations. 
 
 
 
 
Table 6. NECL-5 staining intensity in melanocitic lesions. 
 
 
Western blot RT-PCR. As shown in figure 15 A and B, NECL-5 
expression was significantly higher in WM35, A375 and M14 cell lines 
compared to NHEM (p<0.001). Moreover, analysis with one-way 
ANOVA showed that NECL-5 protein levels were significantly higher 
in M14 and A375 cells compared to those in WM35 cells (p= 0.002). 
 
Flow cytometry. Flow cytometry analysis confirmed the data of western 
blot and RT-PCR about NECL-5 expression in WM35, A375, M14 and 
NHEM cell lines (Figure 15 C). 
 
 
 
 
Figure 15. Protein expression analysis of NECL-5 in normal melanocytes and 
melanoma cell lines. (A) and (B) western blot, (C) flow cytometry. 
 
Gene silencing and tumor invasion assay. Knockdown of NECL-5 gene 
in both A375 and M14 cells was used to understand the effect on cell 
migration. As shown in Figure 16A, the transfection of NECL-5-
specific siRNAs cause an almost 70% loss of NECL-5 transcript levels 
compared to control both in A375 and M14 cells. A reduction of 40% of 
invasive capacity was observed when NECL-5 was knocked-down in 
melanoma cells compared with control cells (p < 0.001; fig. 16B). 
 
 
 
Fig 16. (A) NECL-5 expression after gene silencing. (B) Transwell migration 
after gene silencing. 
 
Gene expression analysis. Transcript levels were higher in primary and 
in metastatic melanoma samples when compared to those of normal 
samples by analyzing several public available melanoma datasets. 
To further confirm the association of NECL-5 with a more malignant 
phenotype in melanoma development, a positive correlation between 
NECL-5 and YY1 transcript levels has been identified by analyzing 
Oncomine software (r=0.468) (Figure 17). In agreement with 
computational identification, immunehisto-chemistry evaluation reveals 
that both NECL-5 and YY1 were concomitantly overexpressed in 
melanoma samples (Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Correlation of YY1 with Necl-5 in melanoma datasets. Heat map of 
genes positively correlated with Necl-5 (r = 0,5) by Pearson correlation analysis in 
Xu melanoma dataset. 
 
 
 
Figure 18. Necl-5 and YY1 immunohistochemistry. Immunohistochemical 
evaluation of Necl-5 (a) and YY1 (b) in a representative melanoma sample. 
 
 
 
 
 
3.6 Discussion 
 
To our knowledge, this is the first report showing the expression of 
NECL-5 in primary and metastatic melanoma tissues and its correlation 
to some clinic-pathological features by using several independent 
approaches. These findings suggest its role in melanoma progression. A 
differential expression of NECL-5 was detected between primary 
melanoma tissues and benign nevi. Only 60% of nevi displayed 
minimal or weak NECL-5 expression, whereas 91.5% of melanoma 
specimens showed a high NECL-5 expression. The immune-positivity 
for NECL-5 protein was significantly different between the benign 
(nevi) and malignant (in situ, invasive and metastatic melanoma) 
lesions; whereas it was substantially absent in normal skin. In benign 
nevi NECL-5 expression was mainly present in the outer zones of the 
rows of melanocytes and seemed to be almost absent in cell-cell 
interfaces between melanocytes, even if in three nevi NECL-5 
immunostaining was present in the epidermis and upper dermis and 
declining with increasing depth. It is possible to speculate that NECL-5 
expression in nevus cells enables them to invade into dermis. Benign 
and atypical nevi have been shown to exist in clinical and histologic 
contiguity with cutaneous melanoma suggesting that these melanocytic 
nevi are also susceptible to malignant transformation (104). These 
findings are consistent with other published reports describing the 
hypotetical role of NECL-5 overexpression in different tumors (97, 99-
103). Most recently, Nakai and coworkers reported that NECL-5 
expression is up-regulated in lung adenocarcinoma and has a negative 
effect on the prognosis of patients (105). Previously, Ochiai and others 
had shown that CD155 expression was up-regulated in several primary 
breast tumors (106). Similarly, Sloan observed that elevated espression 
of CD155 was detected in several primary cancer types (97). In the 
current study, knockdown of the gene encoding NECL-5 in A375 and 
M14 cells caused a reduction of nearly 40% in tumor invasion capacity 
and provided further data that underline the role of NECL-5 in the 
progression of malignant melanoma. 
Our analysis in melanoma tissue specimens showed that the increase in 
NECL-5 immunoreactivity correlated to lymph node involvement and 
Breslow thickness that are considered to be major predictive factors in 
melanoma microstaging (107, 108). These results seem to suggest that 
increased NECL-5 expression correlates to a more aggressive 
behaviour. In agreement with our findings, previous study showed that 
transformed cells gain metastatic ability owing to upregulation of 
NECL-5 (109, 110). 
Many studies have demonstrated that overexpression of NECL-5 is 
implicated in the loss of contact inhibition and epithelial integrity, so to 
enhance cell proliferation and migration; this may in turn contribute to 
the dissemination of cancer cells from the original site (110). 
Interestingly, a novel link between NECL-5 and MMP-2 expression in 
glioblastoma has been demonstrated (111). MMP-2 is strongly 
expressed in malignant melanomas and it correlates with invasion and 
metastatic behavior. This could lead to speculate that the 
overexpression of MMP-2 and NECL-5 might be part of a unique 
altered regulatory program aiming to favour the loss of cell-cell 
adhesion molecules and then cell migration (112). Other studies have 
shown how some substrates of MMP-2 have been associated with 
cancer development and tumor progression, like E-cadherin. The loss of 
E-cadherin in melanocytic lesions would be found initially in nevi and 
more frequently in melanomas, this process appears to be one of the 
critical steps in the progression of melanoma (113). 
Furthermore, the implication of NECL-5 in the aggressiveness of 
melanoma may be corroborated by its correlation to the transcription 
factor YY1. Recent data showed that transcript levels of the 
transcription factor YY1 are higher in several cancer types, including 
melanoma, when compared with those of normal tissue (114-117). 
Previous studies have observed that the inhibition of YY1 in A375 
melanoma cells induces p53-mediated apoptosis after treatment with 
nitric-oxide donor (118). These observations have lead us to investigate 
whether YY1 transcript levels correlate to NECL-5 mRNA levels in 
melanoma. By analyzing the large series of melanoma samples in the 
Xu dataset, we observed that YY1 is positively correlated to NECL-5 (r 
= 0.5), providing further evidence to the idea that its overexpression  is 
associated to a malignant phenotype in melanoma development. 
 
 
 
3.7 Conclusions 
 
In conclusion, we have provided evidence that NECL-5 may be an 
important biomarker in early diagnosis of melanoma, as it is already 
slightly expressed in benign nevi. Moreover, NECL-5 seems to be a 
sensitive indicator of melanoma progression, as it is found strongly 
expressed in metastatic melanoma cell lines. In primary melanoma 
lesions NECL-5 localization seem to suggest his possible involvement 
in the progression toward an invasive phenotype. Limitations of our 
study is the absence of clinical follow-up, including survival data. 
Additional studies of NECL-5 relationship with other adhesion 
molecules and growth factors would be useful to further address the 
complex processes of pathogenesis and progression in malignant 
melanoma. Further future goals will be to determine the molecular and 
cellular consequences of increased NECL-5 expression. These studies 
will allow the linking of NECL-5 to specific altered signaling pathways 
so to contribute to the development of new targeted therapeutic 
strategies. 
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